66 related articles for article (PubMed ID: 30061213)
1. Intratumoral Accumulation and Clonal Expansion May Not Be Decisive for Rejection of Allogeneic Tumors by CD8
Juršėnaitė J; Girkontaitė I; Šiaurys A; Mauricas M; Characiejus D
Anticancer Res; 2018 Aug; 38(8):4481-4484. PubMed ID: 30061213
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescence Imaging of Adoptively Transferred Lymphocytes During Allogeneic Tumor Rejection.
Juršėnaitė J; Girkontaitė I; Mauricas M; Eidukevičius R; Šiaurys A; Characiejus D
Anticancer Res; 2015 Dec; 35(12):6573-6. PubMed ID: 26637871
[TBL] [Abstract][Full Text] [Related]
3. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
4. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
[TBL] [Abstract][Full Text] [Related]
5. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
Ligocki AJ; Brown JR; Niederkorn JY
J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
[TBL] [Abstract][Full Text] [Related]
6. CD8
Du G; Yang N; Gong W; Fang Y; He J; Zhou N; Lu X; Zhao Y
Exp Cell Res; 2017 Jun; 355(1):1-8. PubMed ID: 28232114
[TBL] [Abstract][Full Text] [Related]
7. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
[TBL] [Abstract][Full Text] [Related]
8. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
10. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
12. CD27low natural killer cells prolong allograft survival in mice by controlling alloreactive CD8+ T cells in a T-bet-dependent manner.
Lantow M; Eggenhofer E; Sabet-Baktach M; Renner P; Rovira J; Koehl GE; Schlitt HJ; Geissler EK; Kroemer A
Transplantation; 2015 Feb; 99(2):391-9. PubMed ID: 25606781
[TBL] [Abstract][Full Text] [Related]
13. Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.
Saito H; Okita K; Chang AE; Ito F
Cancer Res; 2016 Jun; 76(12):3473-83. PubMed ID: 27197199
[TBL] [Abstract][Full Text] [Related]
14. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
15. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
16. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
17. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.
Cordaro TA; de Visser KE; Tirion FH; Graus YM; Haanen JB; Kioussis D; Kruisbeek AM
Eur J Immunol; 2000 May; 30(5):1297-307. PubMed ID: 10820375
[TBL] [Abstract][Full Text] [Related]
18. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
[TBL] [Abstract][Full Text] [Related]
19. Exhaustive differentiation of alloreactive CD8+ T cells: critical for determination of graft acceptance or rejection.
Steger U; Denecke C; Sawitzki B; Karim M; Jones ND; Wood KJ
Transplantation; 2008 May; 85(9):1339-47. PubMed ID: 18475193
[TBL] [Abstract][Full Text] [Related]
20. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
